LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Urinalysis Market Driven by Growing Demand for Point-of-Care Diagnostic Testing

By LabMedica International staff writers
Posted on 01 Mar 2023
Print article
Image: The global urinalysis market is expected to reach USD 6.5 billion in 2030 (Photo courtesy of Pexels)
Image: The global urinalysis market is expected to reach USD 6.5 billion in 2030 (Photo courtesy of Pexels)

The global urinalysis market is projected to grow at a CAGR of 6.7% from USD 1.87 billion in 2021 to USD 2.87 billion by 2030, driven by the rising incidence of kidney and urinary tract disorders, growing demand for point-of-care diagnostic testing, increase in aging population and higher healthcare expenditure. In addition, the increasing prevalence of chronic diseases such as diabetes and hypertension, which are linked to kidney and urinary tract disorders, accompanied by technological advancements in urinalysis testing equipment, such as the development of automated urinalysis systems, is expected to fuel market growth.

These are the latest findings of Emergen Research (Vancover, BC, Canada), a market research and consulting company.

The increasing prevalence of kidney diseases and urinary tract infections, particularly among elderly individuals, is a key factor driving the urinalysis market growth. This has been accompanied by the rising occurrences of chronic conditions like diabetes and hypertension, leading to higher incidences of kidney and urinary tract conditions. Additionally, there is an increase in demand for point-of-care diagnostic tests, spurring the development of sophisticated urinalysis testing devices. These devices deliver accurate results quickly, making them a great option for use in ERs, outpatient clinics and other healthcare settings. Technology has also enabled the production of automated urinalysis systems which provide fast and precise results, making them perfect for high-throughput clinical laboratories.

Nevertheless, the market growth could be hindered by the high costs of automated urinalysis systems and other diagnostic testing devices. Additionally, a lack of skilled professionals to carry out diagnostic tests, especially in developing countries, could also impede market growth. Inaccurate results obtained from some urinalysis tests which can lead to misdiagnosis and inadequate treatment can also have a negative impact on market growth. Moreover, the absence of standardization in urinalysis testing processes could affect market growth, as different methods can result in different outcomes, making it difficult to compare results from different labs.

Currently, the urinalysis market is experiencing several trends and innovations including the emergence of advanced urinalysis testing devices and the growing use of point-of-care diagnostic tests. The use of AI and machine learning for urinalysis testing is also a trend that is likely to become more popular in the future. Furthermore, with the increasing demand for easy-to-use portable urinalysis test equipment, particularly in low-income settings, manufacturers are producing innovative devices that are cost-effective and require minimal training to operate.

Geographically, North America is expected to hold the largest revenue share in the global urinalysis market during the forecast period due to the rising prevalence of chronic renal disease, hypertension and diabetes, well-established sophisticated healthcare systems, and significant healthcare expenditure in the region. The European urinalysis market is expected to register a steady revenue growth over the forecast period owing to beneficial reimbursement policies and government guidelines and regulations, as well as developed healthcare infrastructure in the region. The Asia Pacific urinalysis market is expected to register a high revenue growth over the forecast period, thanks to the rapidly developing healthcare industry and increasing investments by key market players.

Related Links:
Emergen Research

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Sekisui Diagnostics UK Ltd.